We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Henoch-Schönlein purpura in children: Use of corticosteroids for prevention and treatment of renal disease.
- Authors
Gohari, Amir; Matsell, Douglas G.; Mammen, Cherry; Goldman, Ran D.
- Abstract
<bold>Question: </bold>A few patients have previously presented to my clinic with palpable purpura, joint inflammation, and severe abdominal pain characteristic of Henoch-Schönlein purpura (HSP). Considering that renal injury is the primary long-term complication of HSP, are corticosteroids effective in preventing or treating renal disease in children with HSP?<bold>Answer: </bold>Henoch-Schönlein purpura is self-limiting in 94% of children, but permanent renal injury is reported in one-fifth of children with nephritic or nephrotic features. Corticosteroids have been considered as candidates for preventing and treating renal involvement in HSP. There is a moderate level of evidence to suggest corticosteroids are not effective in preventing renal involvement in HSP. However, based on low-level evidence and similarities with primary immunoglobulin A nephropathy, experts recommend corticosteroids in treating renal involvement in HSP to prevent long-term kidney injury. Dose and duration of therapy should be carefully considered in consultation with a pediatric nephrologist.
- Publication
Canadian Family Physician / Médecin de Famille Canadien, 2020, Vol 66, Issue 12, p895
- ISSN
0008-350X
- Publication type
journal article
- DOI
10.46747/cfp.6612895